How to Use:

• In vitro: RO4929097 was used at 1-10 µM in vitro.
• In vivo: RO4929097 was administered orally at 10 mg/kg with an intermittent or daily schedule and showed anti-tumor activity in multiple tumor xenograft models.

Reference:

1. 1. Luistro L, et al. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. (2009) Cancer Res. 69(19):7672-80.
2. 2. He W, et al. High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097. (2011) Mol Oncol. 5(3):292-301.
3. 3. Huynh C, et al. The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma. (2011) PLoS One. 6(9):e25264.